Free Cash Flow

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

With gold hitting record highs, investors are keenly awaiting Kinross's update on three critical US projects that could define its production for a decade.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

Amid industry headwinds, Trinity Health invests $2.9B in community health, pioneering a 'care dividend' to tackle housing, food, and access to care.

Peachtree Group's new division closes nearly $30M in its first quarter, capitalizing on a growing credit gap in middle-market equipment finance.

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

The renewable firm secures vital grid access for 2.9 GW in the UK and key approvals in Germany, setting the stage for major project divestments.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

Facing declining revenue but armed with a strong AI vision, Unisys CEO Mike Thomson prepares to address investors at the critical Needham Growth Conference.

EdgeCortix's SAKURA-II processor survives brutal radiation tests, paving the way for intelligent, real-time decision-making on satellites and the Moon.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

With a major new facility planned and a dynamic market, all eyes are on Clean Harbors as it prepares to address investors at two key January events.

CleanSpark boosts Bitcoin output by over 10% and pivots to AI data centers, all while helping stabilize the power grid in times of extreme demand.

In 2025, A&G saved retailers like Rite Aid and expanded its expertise to healthcare and life sciences, showcasing the power of strategic real estate.

Iron Software funds biochar kilns in Chiang Mai, tackling an environmental crisis that threatens the city's 'mini Silicon Valley' status.